Nyxoah

NYXH

Market cap $131M

Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026 Mont-Saint-Guibert, Belgium – April 28, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2026 on Tuesday, May 12, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Robert Taub / Robelga SRL On March 19, 2026, Nyxoah received a transparency notification from Robert Taub and related person Robelga SRL, following the crossing above the 3% threshold by Robelga SRL on December 30, 2025 (while the overall “group” participation did not change).

Nyxoah SA (NYXH) Q4 2025 Earnings Call Transcript

Nyxoah SA (NYXH) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.49 per share a year ago.

REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales Foundation Established to Drive Significant Growth in 2026 Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025. Recent Financial and Operating Highlights Fourth quarter gross revenue of €6.3 million, resulting in net revenue of €5.6 million, which represents 347% year-over-year growth, driven by the first full quarter of US commercialization Full year gross revenue of €11.0 million, resulting in net revenue of €10.0 million, which represents 122% year-over-year growth Fourth quarter gross margin of approximately 64% Cash, cash equivalents and financial assets of €48.0 million at December 31, 2025 145 surgeons trained and 57 accounts activated in the U.S. since commercial launch in August 2025 Genio system consistently reimbursed by both commercial payors and Medicare to date Expanding manufacturing footprint to support global growth “The fourth quarter marked our first full quarter of U.S. commercialization, and we are very pleased with the strong momentum we generated which led to us exceeding our revenue expectations for the quarter,” commented Olivier Taelman, Nyxoah's Chief Executive Officer.

REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), March 13, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BNP Paribas Asset Management On March 11, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA.

Nyxoah to Participate in the Oppenheimer 36 th Annual Healthcare MedTech & Services Conference

Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares on February 20, 2026. Share capital: EUR 6,511,048.19 Total number of securities carrying voting rights: 43,662,403 (all ordinary shares) Total number of voting rights (= denominator): 43,662,403 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 3,416,319 (all granted subscription rights; this number excludes 462,677 subscription rights that were issued but not yet granted) Total number of convertible bonds: 225 convertible bonds with a nominal value of EUR 91,500 per bond Total number of voting rights that can be obtained in case of conversion of all 225 convertible bonds at the current conversion price of EUR 5.00 per share: 4,117,500 * * * Contact: Nyxoah John Landry, CFOIR@nyxoah.com Attachment 2026 02 25 - Press release - Number of shares (ENG)

Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East